Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
- Di Costanzo, Giovan Giuseppe
- Casadei Gardini, Andrea
- Marisi, Giorgia
- Foschi, Francesco Giuseppe
- Scartozzi, Mario
- Granata, Rocco
- Faloppi, Luca
- Cascinu, Stefano
- Silvestris, Nicola
- Brunetti, Oronzo
- Palmieri, Vincenzo Ostilio
- Ercolani, Giorgio
- Tortora, Raffaella
Publication date
January 2017
DOI Publisher
Springer Science and Business Media LLCAbstract
Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC). Nonetheless, it is expensive, effective in few patients, and may cause significant adverse effects. Therefore, accurate selection of patients is needed. In a previous study, we constructed a simple scoring system to predict patients' outcomes based on the occurrence of sorafenib adverse effects
Add to ORKG